UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity

P. Biason, S. Masier, Giuseppe Toffoli

Research output: Contribution to journalArticle

Abstract

Irinotecan is a drug commonly used for the treatment of cancer patients, both as a single agent or in combination therapy. Neutropenia and diarrhea are the dose-limiting toxicities. Genetic variations of proteins involved in irinotecan metabolism and transport have been considered in the development of irinotecan toxicity. In particular, polymorphisms affecting UDP- glucuronosyltransferase isoform 1A1 (UGT1A1) expression or activity are being investigated. Among these, UGT1A1*28 has been considered as the major predictive pharmacogenetic marker for severe hematological toxicity (neutropenia). However, translation to clinical practice of UGT1A1*28 testing as a predictive marker of adverse effects needs to be further investigated and the available data are not conclusive in defining a precise genotype-based dosage. Further prospective studies are required to reach a personalization of chemotherapy with irinotecan.

Original languageEnglish
Pages (from-to)158-165
Number of pages8
JournalJournal of Chemotherapy
Volume20
Issue number2
Publication statusPublished - Apr 2008

Fingerprint

irinotecan
Protein Isoforms
Neutropenia
Pharmacogenetics
Diarrhea
Genotype
Prospective Studies
Drug Therapy
UGT1A1 enzyme
Therapeutics

Keywords

  • APC: 7-ethyl-10-[4-N-(5-amino pentanoic acid)-1-piperidino]- carbonyloxycamptothecin
  • CRC: Colorectal cancer
  • hCE: Human carboxylesterases
  • NPC: 7-ethyl-10-[4-(1-piperidino)-1-amino]- carbonyloxycamptothecin
  • SN38: 7-ethyl-10-hydroxycamptothecin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)
  • Medicine(all)

Cite this

UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. / Biason, P.; Masier, S.; Toffoli, Giuseppe.

In: Journal of Chemotherapy, Vol. 20, No. 2, 04.2008, p. 158-165.

Research output: Contribution to journalArticle

@article{388d65ed3d2d47e594019290751cd9da,
title = "UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity",
abstract = "Irinotecan is a drug commonly used for the treatment of cancer patients, both as a single agent or in combination therapy. Neutropenia and diarrhea are the dose-limiting toxicities. Genetic variations of proteins involved in irinotecan metabolism and transport have been considered in the development of irinotecan toxicity. In particular, polymorphisms affecting UDP- glucuronosyltransferase isoform 1A1 (UGT1A1) expression or activity are being investigated. Among these, UGT1A1*28 has been considered as the major predictive pharmacogenetic marker for severe hematological toxicity (neutropenia). However, translation to clinical practice of UGT1A1*28 testing as a predictive marker of adverse effects needs to be further investigated and the available data are not conclusive in defining a precise genotype-based dosage. Further prospective studies are required to reach a personalization of chemotherapy with irinotecan.",
keywords = "APC: 7-ethyl-10-[4-N-(5-amino pentanoic acid)-1-piperidino]- carbonyloxycamptothecin, CRC: Colorectal cancer, hCE: Human carboxylesterases, NPC: 7-ethyl-10-[4-(1-piperidino)-1-amino]- carbonyloxycamptothecin, SN38: 7-ethyl-10-hydroxycamptothecin",
author = "P. Biason and S. Masier and Giuseppe Toffoli",
year = "2008",
month = "4",
language = "English",
volume = "20",
pages = "158--165",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity

AU - Biason, P.

AU - Masier, S.

AU - Toffoli, Giuseppe

PY - 2008/4

Y1 - 2008/4

N2 - Irinotecan is a drug commonly used for the treatment of cancer patients, both as a single agent or in combination therapy. Neutropenia and diarrhea are the dose-limiting toxicities. Genetic variations of proteins involved in irinotecan metabolism and transport have been considered in the development of irinotecan toxicity. In particular, polymorphisms affecting UDP- glucuronosyltransferase isoform 1A1 (UGT1A1) expression or activity are being investigated. Among these, UGT1A1*28 has been considered as the major predictive pharmacogenetic marker for severe hematological toxicity (neutropenia). However, translation to clinical practice of UGT1A1*28 testing as a predictive marker of adverse effects needs to be further investigated and the available data are not conclusive in defining a precise genotype-based dosage. Further prospective studies are required to reach a personalization of chemotherapy with irinotecan.

AB - Irinotecan is a drug commonly used for the treatment of cancer patients, both as a single agent or in combination therapy. Neutropenia and diarrhea are the dose-limiting toxicities. Genetic variations of proteins involved in irinotecan metabolism and transport have been considered in the development of irinotecan toxicity. In particular, polymorphisms affecting UDP- glucuronosyltransferase isoform 1A1 (UGT1A1) expression or activity are being investigated. Among these, UGT1A1*28 has been considered as the major predictive pharmacogenetic marker for severe hematological toxicity (neutropenia). However, translation to clinical practice of UGT1A1*28 testing as a predictive marker of adverse effects needs to be further investigated and the available data are not conclusive in defining a precise genotype-based dosage. Further prospective studies are required to reach a personalization of chemotherapy with irinotecan.

KW - APC: 7-ethyl-10-[4-N-(5-amino pentanoic acid)-1-piperidino]- carbonyloxycamptothecin

KW - CRC: Colorectal cancer

KW - hCE: Human carboxylesterases

KW - NPC: 7-ethyl-10-[4-(1-piperidino)-1-amino]- carbonyloxycamptothecin

KW - SN38: 7-ethyl-10-hydroxycamptothecin

UR - http://www.scopus.com/inward/record.url?scp=44849107763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849107763&partnerID=8YFLogxK

M3 - Article

C2 - 18467239

AN - SCOPUS:44849107763

VL - 20

SP - 158

EP - 165

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 2

ER -